Ibuprofen Favors Binding of Amyloid-β Peptide to Its Depot, Serum Albumin
2022
Ekaterina A. Litus | Alexey S. Kazakov | Evgenia I. Deryusheva | Ekaterina L. Nemashkalova | Marina P. Shevelyova | Andrey V. Machulin | Aliya A. Nazipova | Maria E. Permyakova | Vladimir N. Uversky | Sergei E. Permyakov
The deposition of amyloid-β peptide (Aβ) in the brain is a critical event in the progression of Alzheimer’s disease (AD). This Aβ deposition could be prevented by directed enhancement of Aβ binding to its natural depot, human serum albumin (HSA). Previously, we revealed that specific endogenous ligands of HSA improve its affinity to monomeric Aβ. We show here that an exogenous HSA ligand, ibuprofen (IBU), exerts the analogous effect. Plasmon resonance spectroscopy data evidence that a therapeutic IBU level increases HSA affinity to monomeric Aβ<sub>40</sub>/Aβ<sub>42</sub> by a factor of 3–5. Using thioflavin T fluorescence assay and transmission electron microcopy, we show that IBU favors the suppression of Aβ<sub>40</sub> fibrillation by HSA. Molecular docking data indicate partial overlap between the IBU/Aβ<sub>40</sub>-binding sites of HSA. The revealed enhancement of the HSA–Aβ interaction by IBU and the strengthened inhibition of Aβ fibrillation by HSA in the presence of IBU could contribute to the neuroprotective effects of the latter, previously observed in mouse and human studies of AD.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals
